Adverse reactions observed with Escitalopram are most frequent during the ﬁrst one or two weeks of treatment and may decrease in intensity and frequency with continued treatment.
After prolonged administration abrupt, cessation of Escitalopram may produce withdrawal reactions in some patients.
Uncommon: Postural hypotension.
Metabolic and nutritional disorders:
Common: Decreased appetite. Incidence unknown: Hyponatraemia, inappropriate ADH secretion.
Incidence unknown: Hallucinations, mania, confusion, agitation, anxiety, depersonalization, panic attacks, nervousness.
Common: Insomnia, somnolence, dizziness, fatigue, drowsiness. Uncommon: Sleep disorder, taste disorder. Incidence unknown: Seizures, tremor, movement disorders, serotonin syndrome (typically characterised by a rapid onset of changes in mental state with confusion, mania, agitation, hyperactivity, shivering, fever, tremor, ocular movements, myoclonus, hyperreﬂexia and incoordination).
Respiratory, thoracic and mediastinal disorders:
Common: Sinusitis, yawning.
Common: Nausea, vomiting, diarrhoea, constipation, anorexia. Incidence unknown: Dry mouth.
Incidence unknown: Abnormal liver function tests.
Skin and subcutaneous tissue disorders:
Common: Increased sweating. Incidence unknown: Rash, pruritus, ecchymoses, angioedema.
Musculoskeletal, connective tissue and bone disorders:
Incidence unknown: Arthralgia, myalgia.
Renal and urinary disorders:
Incidence unknown: Urinary retention.
Reproductive system and breast disorders:
Common: Decreased libido (men and women), ejaculation disorder and impotence (male), anorgasmia (female), galactorrhoea.
Uncommon: Abnormal vision.
Common: Pyrexia. Incidence unknown: Anaphylactic reactions.